Spinventure
VC Fund
Angleur, Belgium
Spinventure is a VC fund in Angleur focused on Health Care and Biotechnology. Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Spinventure invests in
Stages Spinventure invests in
Countries Spinventure invests in
Round sizes
Round size
- Series A
- $768k–$15M
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Medical Device 2 (33%)
- Therapeutics 1 (17%)
Stage
- Series A 4 (67%)
- Funding Round 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Convert Pharmaceuticals
|
Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit.Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. | $14.9M / Series A / Feb 28, 2018 | |
|
Convert Pharmaceuticals
|
Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit.Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance toconventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. | $17.1M / Seed / Feb 28, 2018 | |
Dim3
|
Dim3 develops and markets innovative clinical expert platforms and medical devices. Our solutions speed up medical decisions, enhance the life of patients and reduce healthcare costs.Now on the market, DIM3 first platform focuses on the fight against disease-related malnutrition. This is a major but silent threat that costs lives and anestimated 170 billions euros/year for Europe only. | $4.4M / Sep 26, 2017 | |
Elysia
|
Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals. | $1.3M / Series A / Jun 30, 2015 | |
2-Observe
|
2-Observe company is active in observational research and validation of innovative concepts in the biotechnology sector and private health care.Founded in 2010, 2-Observe company was born from the concern of its founders of meeting the needs observed in the field by providing effective solutions to improve quality of life. It was built from theexperience of its associates from the medical community, the research sector and the industry field of life sciences.Jean-Philippe Hermanne MD, Internist and Head of Department of Oncology in the Centre Hospitalier Régional of Namur (Belgium), with expertise in intensive care and emergency services.Isabelle Joslet, Specialist in Public Health with a long experience as Coordinator of university research programs.Pierre Bothy, Senior Consultant in the medical device industry. | $768K / Series A / Jun 17, 2015 | |
Okapi Sciences
|
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination ofindividuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises. | $9.3M / Series A / Nov 03, 2008 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Spinventure invest in?
Spinventure invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Spinventure's check size?
Spinventure typically joins rounds of $768k–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Spinventure participates in.
When did Spinventure last invest?
The most recent investment recorded for Spinventure closed in Feb 2018. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
